MiMedx EBITDA vs. Current Valuation
| MDXG Stock | USD 9.25 0.18 1.91% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 40.5 M | Current Value 42.5 M | Quarterly Volatility 25 M |
For MiMedx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MiMedx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MiMedx Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MiMedx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MiMedx Group over time as well as its relative position and ranking within its peers.
MiMedx |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.57 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
MiMedx Group Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining MiMedx's current stock value. Our valuation model uses many indicators to compare MiMedx value to that of its competitors to determine the firm's financial worth. MiMedx Group is considered to be number one stock in ebitda category among its peers. It is regarded fifth in current valuation category among its peers reporting about 32.48 of Current Valuation per EBITDA. At this time, MiMedx's EBITDA is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value MiMedx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.MiMedx Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
MiMedx |
| = | 40.52 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
MiMedx |
| = | 1.32 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
MiMedx Current Valuation vs Competition
MiMedx Group is regarded fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 15.09 Billion. MiMedx holds roughly 1.32 Billion in current valuation claiming about 9% of equities under Health Care industry.
MiMedx Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in MiMedx, profitability is also one of the essential criteria for including it into their portfolios because, without profit, MiMedx will eventually generate negative long term returns. The profitability progress is the general direction of MiMedx's change in net profit over the period of time. It can combine multiple indicators of MiMedx, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -215.1 M | -204.4 M | |
| Operating Income | 37.1 M | 39 M | |
| Income Before Tax | 30.6 M | 32.2 M | |
| Total Other Income Expense Net | -6.5 M | -6.2 M | |
| Net Income | 67.4 M | 70.8 M | |
| Income Tax Expense | -36.8 M | -35 M | |
| Net Income From Continuing Ops | 4.3 M | 4.6 M | |
| Net Loss | -33.1 M | -31.4 M | |
| Non Operating Income Net Other | -20.7 K | -21.7 K | |
| Net Interest Income | -6.3 M | -6.6 M | |
| Change To Netincome | 19.3 M | 14.4 M | |
| Net Income Per Share | 0.58 | 0.61 | |
| Income Quality | 0.40 | 0.38 | |
| Net Income Per E B T | 2.20 | 1.46 |
MiMedx Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on MiMedx. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of MiMedx position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the MiMedx's important profitability drivers and their relationship over time.
Use MiMedx in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MiMedx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MiMedx will appreciate offsetting losses from the drop in the long position's value.MiMedx Pair Trading
MiMedx Group Pair Trading Analysis
The ability to find closely correlated positions to MiMedx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MiMedx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MiMedx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MiMedx Group to buy it.
The correlation of MiMedx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MiMedx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MiMedx Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MiMedx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your MiMedx position
In addition to having MiMedx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Funds Thematic Idea Now
Tech Funds
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project MiMedx's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of MiMedx Group at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include MiMedx's income statement, its balance sheet, and the statement of cash flows.